Skip to main content
Shop Plans Learn more about our coverage options including health, Medicare, dental and vision options for you, your family or your employees. Get Started Individual & Family Medicare Employer Vision Dental International Travel Find Care FAQ Blog Members Stay on top of your health care with helpful member resources. Members Home Medicare Health Dental Vision Find Care Member Knowledge Center Member Forms Medicare Forms Library Make a Payment Federal Employees Student Blue Healthy Blue Providers Access tools, policies and the latest information to help you care for our members. Providers Home Network Participation Networks & Programs Claims, Appeals & Inquiries Prior Authorization Services & CPT codes Prescription Drug Search Policies, Guidelines & Codes Provider News Provider FAQ Contact Us Employers Learn about our coverage options for small and large employers, and access tools and resources for your group. Employers Home Shop Employer Plans Employer Portal Support Member Forms & Resources Find Care Blog Agents Access the tools you need: rate quotes, applications, forms, the latest industry news, marketing materials and more. Agents Home Agent Services Check Eligibility Find Care Member Forms & Resources Medicare Forms Library
Contact Us
Log In
I am ... Please select A member A provider An employer An agent
Log in to Agent Services
Log in to Employer Services Register for Employer Services I'm registered but need portal access
Username Forgot username? Continue to Log In Register for Blue Connect Need help? Learn how to log in.
Log in to Blue e Register for Blue e Log in to Dental Blue
Back
Updates to Blue Cross NC preferred Injectable Oncology Program policy and White Blood Cell Growth Factor policy, effective April 1, 2024 March 01, 2024 Pharmacy

Effective April 1, 2024, Blue Cross and Blue Shield of North Carolina (Blue Cross NC) will be updating our preferred Injectable Oncology Program policy and White Blood Cell Growth Factor policy.

Preferred Injectable Oncology Program policy

We are updating our preferred trastuzumab biosimilar products to include Kanjinti and Trazimera as of April 1, 2024 (previously Kanjinti and Ogivri). With this change, starting April 1, 2024, Ogivri will change to a non-preferred trastuzumab biosimilar product and will have prior authorization added, and Trazimera will have prior authorization removed. See list below.

White Blood Cell Growth Factors policy

We are updating our preferred pegfilgrastim biosimilar products to include Fulphila and Nyvepria as of April 1, 2024 (previously Udenyca and Ziextenzo). With this change, starting April 1, 2024, Udenyca/Udenyca Onbody and Ziextenzo will change to non-preferred pegfilgrastim biosimilar products and will have prior authorization added, and Fulphila and Nyvepria will have prior authorization removed. See list below.

Preferred Trastuzumab Containing Agent(s) (Unrestricted)

  • Kanjinti (trastuzumab-anns)
  • Trazimera (trastuzumab-qyyp)

Non-Preferred Trastuzumab Containing Agent(s)

  • Herceptin® (trastuzumab)
  • Herzuma® (trastuzumab-pkrb)
  • Ontruzant (trastuzumab-dttb)
  • Ogivri (trastuzumab-dkst)
  • Herceptin Hylecta (trastuzumab and hyaluronidase-oysk)

Preferred Pegfilgrastim Products (Unrestricted)

  • Fulphila® (pegfilgrastim-jmdb)
  • Nyvepria (pegfilgrastim-apgf)

Non-Preferred Long-Acting/Pegfilgrastim Products

  • Fylnetra® (pegfilgrastim-pbbk)
  • Neulasta®, Neulasta® OnPro® (pegfilgrastim)
  • Stimufend® (pegfilgrastim-fpgk)
  • Rolvedon (eflapegrastim-xnst)
  • Udenyca®, Udenyca Onbody (pegfilgrastim-cbqv)
  • Ziextenzo® (pegfilgrastim-bmez)
  • Ryzneuta® (efbemalenograstim alfa-vuxw)

Actions Required Due to These Changes

Providers with members on impacted drugs should utilize these preferred products before using non-preferred products. Any members who are currently using a non-preferred biosimilar drug should be moved to our preferred products as soon as possible.

Providers requesting prior authorization for a non-preferred product on or after April 1, 2024, for an applicable Commercial member will need to submit the request through MHK (accessed via Blue e). No action is needed prior to April 1, 2024.